Sponsor:
Darcy Krueger
Code:
NCT05104983
Conditions
Tuberous Sclerosis Complex
Epilepsy
Eligibility Criteria
Sex: All
Age: 0
Healthy Volunteers: Not accepted
Interventions
Sirolimus
Placebo
Brief summary:
Conditions
Tuberous Sclerosis Complex
Epilepsy
Study ID
NCT05104983
Start date
Oct 13, 2021
Status verified date
Jan, 2026
Completion date
Jun 30, 2027
Anticipated
Primary completion date
Jun 30, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 0
Healthy Volunteers: Not accepted
Enrollment
64 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Prevention
Arms
experimental: Sirolimus
placebo comparator: Placebo
Interventions
Sirolimus
Placebo
Primary outcome measure
Central contacts
Locations
University of Alabama at Birmingham
Recruiting
Birmingham, Alabama, United States, 35294
Principal Investigator:
E. Martina Bebin, MD, MPA
University of California at Los Angeles
Recruiting
Los Angeles, California, United States, 90095
Principal Investigator:
Rajsekar Rajamaran, MD, MS
Stanford University
Recruiting
Palo Alto, California, United States, 94304
Contacts
Rayann Solidum
rsolidum@stanford.eduPrincipal Investigator:
Brenda Porter, MD
Children's Hospital Colorado
Recruiting
Aurora, Colorado, United States, 80045
Contacts
Principal Investigator:
Kevin Ess, MD
Lurie Children's Hospital of Chicago
Recruiting
Chicago, Illinois, United States, 60611
Contacts
Principal Investigator:
Tracy Gertler, MD
Boston Children's Hospital
Recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator:
Mustafa Sahin, MD, PhD
Washington University -- St. Louis
Recruiting
St Louis, Missouri, United States, 63110
Principal Investigator:
Michael Wong, MD, PhD
Cincinnati Children's Hospital Medical Center
Recruiting
Cincinnati, Ohio, United States, 45229
Contacts
Principal Investigator:
Darcy A Krueger, MD, PhD
University of Texas HSC at Houston
Recruiting
Houston, Texas, United States, 77030
Principal Investigator:
Hope Northrup, MD
Seattle Children's Hospital
Recruiting
Seattle, Washington, United States, 98105
Principal Investigator:
Stephanie Randle, MD
Sponsor
Darcy Krueger
Last update posted
Jan 22, 2026
Last verified
Jan, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Darcy Krueger on 2026-01-22.